Trial Profile
Safety and Efficacy of Recombinant Human Bone Morphogenetic Protein 2 on Cranial Defect Closure in the Pediatric Population.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2015
Price :
$35
*
At a glance
- Drugs BMP 2 (Primary)
- Indications Bone disorders
- Focus Therapeutic Use
- 25 Sep 2015 New trial record